Alterity Therapeutics Limited Stock
Stocks
ATH
AU0000043945
Biotechnology & Medical Research
OTC Markets Traded|
Delayed
Australian S.E.
12:13:49 28/10/2026 HKT
|
5-day change | 1st Jan Change | ||
| 0.2450 AUD | +2.08% |
|
-3.92% | -38.75% |
| 10-05 | Alterity Therapeutics Limited Presents New Analyses of Ath434 Phase 2 Data in Multiple System Atrophy | CI |
| 09-16 | Lake Street Initiates Alterity Therapeutics at Buy With $10 Price Target | MT |
| Market Cap | 38.67M 34.71M 32.05M 29.06M 54.32M 3.67B 54.98M 384M 153M 1.93B 145M 142M 6.11B | P/E 2027 * |
-2.34x | P/E 2028 * | -0.22x |
|---|---|---|---|---|---|
| Enterprise Value | 28.72M 25.78M 23.8M 21.58M 40.34M 2.73B 40.83M 285M 113M 1.43B 108M 105M 4.53B | EV / Sales 2027 * |
26.5x | EV / Sales 2028 * | 0.89x |
| Free-Float |
96.2% | Yield 2027 * |
-
| Yield 2028 * | - |
| Markets | Quality | ||
|---|---|---|---|
Australian S.E.
| ATH | Delayed | |
OTC Markets
| PRNAF | Delayed | |
|
Deutsche Boerse AG
| PBN | Delayed | |
|
Börse Stuttgart
| PBN | Delayed |
Last Transcript: Alterity Therapeutics Limited
| 1 day | +2.08% | ||
| 1 week | -3.92% | ||
| Current month | -39.13% | ||
| 1 month | -38.75% | ||
| 3 months | -53.77% | ||
| 6 months | -51.00% | ||
| Current year | -38.75% |
| 1 week | 0.23 |  | 0.27 |
| 1 month | 0.23 | | 0.44 |
| Current year | 0.23 | | 0.78 |
| 1 year | 0.23 | | 0.78 |
| 3 years | 0.1 | | 0.95 |
| 5 years | 0.1 | | 1.6 |
| 10 years | 0.1 | | 20.5 |
| Manager | Title | Age | Since |
|---|---|---|---|
David Stamler
CEO | Chief Executive Officer | 65 | 07/01/2021 |
| Director of Finance/CFO | - | 30/09/2024 | |
| Chief Tech/Sci/R&D Officer | - | 01/04/2019 |
| Director | Title | Age | Since |
|---|---|---|---|
Peter Marks
BRD | Director/Board Member | 70 | 29/07/2005 |
Lawrence Gozlan
BRD | Director/Board Member | 47 | 08/08/2011 |
David Stamler
BRD | Director/Board Member | 65 | 21/11/2025 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 31/8/26 | Exercice | Director | 47,620 | 0.0216% | ||
| 31/8/26 | Buy | Chief Executive Officer | -47,620 | 0.0216% | ||
| 31/8/26 | Buy | Director | 95,240 | 0.0432% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.08% | -3.92% | -55.45% | -30.00% | 42.61M | |
| -3.10% | -4.19% | +32.67% | +59.47% | 65.28B | |
| +0.33% | +0.33% | +10.16% | +78.07% | 54.57B | |
| +0.16% | +1.73% | +9.89% | +102.10% | 53.59B | |
| -0.75% | +1.38% | +24.89% | +50.91% | 45.03B | |
| -1.30% | -4.80% | +16.05% | +114.76% | 42.17B | |
| +1.26% | -5.26% | +221.12% | +900.64% | 39.42B | |
| -0.74% | -4.46% | +11.00% | +44.65% | 32.71B | |
| +1.11% | +15.18% | +60.27% | +49.33% | 26.5B | |
| +3.18% | -6.72% | +25.35% | -8.75% | 24.01B | |
| Average | +0.22% | -1.87% | +35.60% | +136.12% | 38.33B | |
| Weighted average by Cap. | -0.35% | -0.59% | +42.51% | +153.40% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 1.08M 973K 898K 814K 1.52M 103M 1.54M 10.77M 4.28M 53.95M 4.07M 3.98M 171M | 1.95M 1.75M 1.62M 1.47M 2.74M 186M 2.78M 19.41M 7.71M 97.27M 7.33M 7.18M 308M |
| Net income | -27.31M -24.51M -22.63M -20.52M -38.36M -2.59B -38.83M -271M -108M -1.36B -103M -100M -4.31B | -30.69M -27.55M -25.44M -23.07M -43.11M -2.92B -43.64M -305M -121M -1.53B -115M -113M -4.85B |
| Net Debt | -9.95M -8.93M -8.25M -7.48M -13.98M -945M -14.15M -98.89M -39.27M -496M -37.36M -36.56M -1.57B | -36.93M -33.15M -30.61M -27.75M -51.87M -3.51B -52.51M -367M -146M -1.84B -139M -136M -5.83B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 28/10/26 | A$0.2450 | +2.08% | 111,168 |
| 27/10/26 | A$0.2400 | -9.43% | 102,728 |
| 26/10/26 | A$0.2650 | +3.92% | 235,561 |
| 23/10/26 | A$0.2550 | -3.77% | 134,037 |
| 22/10/26 | A$0.2650 | +3.92% | 395,725 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ATH Stock
Select your edition
All financial news and data tailored to specific country editions
